John A. Harris

This study identifies FDA-approved compounds that inhibit ExoU, a virulence factor in Pseudomonas aeruginosa, and shows their efficacy in reducing corneal infection severity in multiple models.

This paper introduces FLEX, a fusion tag derived from FGF1 that enhances protein expression, solubility, and purity across different systems.

This study identifies TRIB2 as a therapeutic target in AML by demonstrating that its degradation via PROTACs and small molecules can reverse chemoresistance and enhance chemotherapy efficacy.

The paper identifies sulfotyrosine (sY) sites in the human phosphoproteome by distinguishing them from phosphorylation using mass error shifts and filters out false positives, finding 31 convincing sY sites.